Literature DB >> 11815571

An investigation of the antimicrobial effects of linezolid on bacterial biofilms utilizing an in vitro pharmacokinetic model.

Sarah Gander1, Katy Hayward, Roger Finch.   

Abstract

Biofilms of methicillin-susceptible and -resistant Staphylococcus aureus, a strain of coagulase-negative staphylococcus and glycopeptide-intermediate strains of S. aureus (GISA) were exposed to the oxazolidinone linezolid, and four comparator antibiotics (quinupristin/ dalfopristin, vancomycin, teicoplanin and ciprofloxacin) using a Sorbarod model. The effects of these antibiotics were assessed by monitoring the reduction in the number of cells eluted from the biofilms. The biofilms were exposed to the antibiotics by two methods. The first was an exponentially decreasing drug concentration method, where the rate of dilution was matched to the half-lives of the antibiotics and the initial concentration matched peak serum levels. The second was a constant drug concentration method, in which biofilms were exposed to antibiotics for 2 h, with the concentration of the antibiotic equalling the total amount of drug used in the exponentially decreasing method. The results indicate that linezolid produces a greater reduction in the number of cells eluted with the exponentially decreasing method compared with the constant concentration exposure against all strains tested except for one of the GISA strains, Mu 50. Overall, ciprofloxacin produced the greatest effects in the exponentially decreasing concentration experiments, but only against non-resistant strains. In the constant concentration exposure no one drug was responsible for the largest reductions in cell numbers observed. Linezolid and quinupristin/dalfopristin produced a reduction in the number of cells eluted from the biofilms of all of the strains tested in both methods of exposure and should be considered for further clinical studies of the treatment of staphylococcal biofilm-associated infections.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11815571     DOI: 10.1093/jac/49.2.301

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  Staphylococcus aureus biofilm as a target for single or repeated doses of oxacillin, vancomycin, linezolid and/or lysostaphin.

Authors:  E Walencka; B Sadowska; S Rózalska; W Hryniewicz; B Rózalska
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.099

Review 2.  Linezolid treatment of ventriculoperitoneal shunt infection without implant removal.

Authors:  P Castro; A Soriano; C Escrich; G Villalba; M Sarasa; J Mensa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-09       Impact factor: 3.267

3.  Polymeric nanofiber coating with tunable combinatorial antibiotic delivery prevents biofilm-associated infection in vivo.

Authors:  Alyssa G Ashbaugh; Xuesong Jiang; Jesse Zheng; Andrew S Tsai; Woo-Shin Kim; John M Thompson; Robert J Miller; Jonathan H Shahbazian; Yu Wang; Carly A Dillen; Alvaro A Ordonez; Yong S Chang; Sanjay K Jain; Lynne C Jones; Robert S Sterling; Hai-Quan Mao; Lloyd S Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-24       Impact factor: 11.205

4.  Linezolid compared with eperezolid, vancomycin, and gentamicin in an in vitro model of antimicrobial lock therapy for Staphylococcus epidermidis central venous catheter-related biofilm infections.

Authors:  John Curtin; Martin Cormican; Gerard Fleming; John Keelehan; Emer Colleran
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

5.  Antifungal activity of amphotericin B and voriconazole against the biofilms and biofilm-dispersed cells of Candida albicans employing a newly developed in vitro pharmacokinetic model.

Authors:  Mohamed El-Azizi; Noha Farag; Nancy Khardori
Journal:  Ann Clin Microbiol Antimicrob       Date:  2015-04-03       Impact factor: 3.944

6.  Growth of MRSA and Pseudomonas aeruginosa in a fine-celled foam model containing sessile commensal skin bacteria.

Authors:  Angela Oates; Andrew J McBain
Journal:  Biofouling       Date:  2016       Impact factor: 3.209

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.